Increased Circulating Th17 Cell Populations in Patients with Pancreatic Ductal Adenocarcinoma

Overview

Journal Immunogenetics

Specialties Allergy & Immunology
Genetics

Date 2023 Aug 4

PMID 37540314

Authors

Imteyaz Ahmad Khan

Nidhi Singh

Deepak Gunjan

Srikant Gopi

Nihar Ranjan Dash

Surabhi Gupta

Anoop Saraya

Affiliations

Soon will be listed here.

Abstract

T-helper 17 (Th17) cells are a subset of CD4 helper T cells that produce interleukin 17 (IL-17) and play a crucial role in the pathogenesis of inflammatory and autoimmune diseases. Few studies have been conducted to determine the role of Th17 cells in the tumorigenesis and development of pancreatic ductal adenocarcinoma (PDAC); however, its role is still unclear. In this study, the percentage of circulating Th17 cells and serum levels of IL-17A and IL-23 were analyzed using flow cytometry and ELISA, respectively, in 40 PDAC patients, 30 chronic pancreatitis (CP) patients and 30 healthy controls (HC). In addition, the mRNA expression levels of IL-17A, STAT3 and RORγt in tissue samples were quantified by qRT-PCR. The results showed that the percentage of circulating Th17 cells and the concentrations of serum IL-17A and IL-23 were significantly increased in PDAC patients as compared to CP and HC (P < 0.001). In addition, the higher level of IL-17A was significantly correlated with the poor overall survival of the PDAC patients. Furthermore, the frequencies of Th17 cells and IL-17A were significantly higher in stage III+IV PDAC patients versus stage I+II. A significant increase in IL-17A, STAT3 and RORγT mRNA was observed in patients with PDAC. Taken together, these findings suggest that the increased circulating Th17 cells and serum IL-17A may be involved in the development and metastasis of PDAC, and thus represent potential targets for the treatment of PDAC.

Citing Articles

The role of interleukin-17 in inflammation-related cancers.

Zhang X, Li B, Lan T, Chiari C, Ye X, Wang K Front Immunol. 2025; 15:1479505.

PMID: 39906741 PMC: 11790576. DOI: 10.3389/fimmu.2024.1479505.

Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer.

Abal-Sanisidro M, De Luca M, Roma S, Ceraolo M, Fuente M, De Monte L Int J Mol Sci. 2024; 25(15).

PMID: 39125655 PMC: 11312284. DOI: 10.3390/ijms25158085.

Circulating Biomarkers Involved in the Development of and Progression to Chronic Pancreatitis-A Literature Review.

Poulsen V, Hadi A, Werge M, Karstensen J, Novovic S Biomolecules. 2024; 14(2).

PMID: 38397476 PMC: 10887223. DOI: 10.3390/biom14020239.

Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic Cancer.

Chen Z, Qiao S, Yang L, Sun M, Li B, Lu A Int J Mol Sci. 2023; 24(17).

PMID: 37686343 PMC: 10487659. DOI: 10.3390/ijms241713539.

References

Cascao R, Moura R, Perpetuo I, Canhao H, Vieira-Sousa E, Mourao A . Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther. 2010; 12(5):R196. PMC: 2991033. DOI: 10.1186/ar3168. View

Charles K, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A . The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009; 119(10):3011-23. PMC: 2752076. DOI: 10.1172/JCI39065. View

Chung Y, Chang S, Martinez G, Yang X, Nurieva R, Kang H . Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 2009; 30(4):576-87. PMC: 2705871. DOI: 10.1016/j.immuni.2009.02.007. View

Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul J . FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25):2395-2406. DOI: 10.1056/NEJMoa1809775. View

Duan Z, Miller H, Fu X, Ge D, Jin B, Moustafa A . Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer. Am J Clin Exp Urol. 2019; 7(4):249-261. PMC: 6734037. View

Egwuagu C . STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine. 2009; 47(3):149-56. PMC: 2733795. DOI: 10.1016/j.cyto.2009.07.003. View

Elessawi D, Alkady M, Ibrahim I . Diagnostic and prognostic value of serum IL-23 in colorectal cancer. Arab J Gastroenterol. 2019; 20(2):65-68. DOI: 10.1016/j.ajg.2019.05.002. View

Fouser L, Wright J, Dunussi-Joannopoulos K, Collins M . Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev. 2009; 226:87-102. DOI: 10.1111/j.1600-065X.2008.00712.x. View

Gnerlich J, Mitchem J, Weir J, Sankpal N, Kashiwagi H, Belt B . Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol. 2010; 185(7):4063-71. PMC: 3693576. DOI: 10.4049/jimmunol.0902609. View

10.

He S, Fei M, Wu Y, Zheng D, Wan D, Wang L . Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci. 2011; 12(11):7424-37. PMC: 3233413. DOI: 10.3390/ijms12117424. View

11.

Hirota K, Martin B, Veldhoen M . Development, regulation and functional capacities of Th17 cells. Semin Immunopathol. 2010; 32(1):3-16. DOI: 10.1007/s00281-009-0187-y. View

12.

Huang J, Lok V, Ngai C, Zhang L, Yuan J, Lao X . Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2020; 160(3):744-754. DOI: 10.1053/j.gastro.2020.10.007. View

13.

Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M . Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep. 2011; 25(5):1271-7. DOI: 10.3892/or.2011.1201. View

14.

Ivanov I, McKenzie B, Zhou L, Tadokoro C, Lepelley A, Lafaille J . The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126(6):1121-33. DOI: 10.1016/j.cell.2006.07.035. View

15.

Karabulut S, Afsar C, Karabulut M, Alis H, Kilic L, Cikot M . Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma. J Gastrointest Cancer. 2015; 47(1):47-54. DOI: 10.1007/s12029-015-9787-z. View

16.

Karpisheh V, Ahmadi M, Abbaszadeh-Goudarzi K, Mohammadpour Saray M, Barshidi A, Mohammadi H . The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell Int. 2022; 22(1):108. PMC: 8897940. DOI: 10.1186/s12935-022-02528-8. View

17.

Korn T, Bettelli E, Oukka M, Kuchroo V . IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27:485-517. DOI: 10.1146/annurev.immunol.021908.132710. View

18.

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S . Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009; 114(6):1141-9. PMC: 2723011. DOI: 10.1182/blood-2009-03-208249. View

19.

Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J . Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007; 178(11):6730-3. DOI: 10.4049/jimmunol.178.11.6730. View

20.

Lafdil F, Miller A, Ki S, Gao B . Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol. 2010; 7(4):250-4. PMC: 3732654. DOI: 10.1038/cmi.2010.5. View